Uniqure
Founded 1998 · 320 employees on LinkedIn · 6 known investors
Find your way into Uniqure
Sign up to see every warm intro you have to Uniqure
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Uniqure team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
uniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
Founders & leadership
MK

Matthew KapustaChief Executive OfficerMatthew Kapusta is Chief Executive Officer of uniQure, a biotech company developing gene therapies for serious genetic diseases. He joined the company as Chief Financial Officer in 2015 after two decades in the life sciences industry, with prior roles in corporate development at AngioDynamics, finance at Smith & Nephew Orthopaedics, and healthcare investment banking. Kapusta holds an MBA from NYU Stern and a BBA from University of Michigan's Ross School of Business.
Investors · 6
Advent Life Scienceslisted by Advent Life SciencesLondon
How we know: Advent Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
ALS Investment Fundlisted by ALS Investment FundAmsterdam
How we know: ALS Investment Fund's portfolio page · Not right? Tell us
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · Not right? Tell us
Founder mafia
4 people who came through Uniqure went on to found or lead other companies.
Frequently asked questions
- What does Uniqure do?
- uniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
- Who are Uniqure's investors?
- Uniqure's investors include Advent Life Sciences, ALS Investment Fund, Foresite Capital, HEALTHCARE ROYALTY PARTNERS, Ridgeback Capital, Forbion.





